Thank you, Manny, and good morning, everyone. It was another quarter of meaningful progress and significant change for Mistras. And Project Phoenix will fundamentally change our company and significantly increase shareholder value. But before highlighting these changes, let me provide some highlights for the quarter. For the third quarter of 2023, consolidated revenue was up slightly, primarily reflecting growth in oil and gas, in addition to continued strength in several of our key growth initiatives, particularly commercial aerospace and Data Analytical Solutions. I would also note that revenue in our International segment was up 21% in the quarter, driven primarily by a strong turnaround market and increased aerospace and defense volume. Gross profit margin expanded 20 basis points as compared to the prior year quarter and was also up 210 basis points on a sequential basis, driven primarily by a favorable sales mix and lower healthcare expenses, somewhat offset by inflationary pressures, including rising energy costs and incremental subcontractor costs. Selling, general and administrative expenses were down 3% compared to the third quarter of 2022 and were also down 4.7% sequentially from the second quarter of 2023. As Manny mentioned earlier, this decrease largely reflects the impact of Project Phoenix and ongoing cost controls to achieve sustained overhead savings. Loss from operations was $4.7 million for the third quarter, yet income from operations before special items of $11.8 million on a non-GAAP basis when excluding the goodwill impairment charge and reorganization and other related costs associated with Project Phoenix. The non-GAAP income from operations represents a 19% increase as compared to the prior year period. Net loss for the third quarter was $10.3 million, or negative $0.34 per diluted share, before adjusting for the same aforementioned items, while adjusted EBITDA in the quarter was up 12.5% to $20.9 million, meeting our expectations. The net loss in the quarter was largely attributable to a non-cash impairment charge of $13.8 million related to our International segment, related to macroeconomic factors in Europe, before consideration of the impact of any prospective Project Phoenix benefits. I will provide more detail on this item in a few minutes. Net income on a non-GAAP basis, excluding the aforementioned special items, was $5.6 million or $0.18 per diluted share for the quarter. Our net cash provided by operating activities was $10.7 million for the first nine months of 2023 compared to $10.5 million in the prior year period. Free cash flow was negative $5.6 million for the first nine months of 2023 compared to positive $0.9 million in the prior year period. This decrease in cash flow, free cash flow, was primarily attributable to an increase in capital expenditures during the current year and higher than normal accounts receivable balances as of September 30th, due to the timing of projects in the third quarter. This $6.6 million increase in capital expenditures during the current year reflects investments in our shop laboratories and in Data Analytical Solutions offerings to foster future revenue growth. Gross debt increased by $10.2 million during the quarter ended September 30, from $183.7 million as of June 30, 2023 to $193.9 million as of September 30, primarily due to the aforementioned factors impacting cash flow. Our trailing 12-month bank-defined leverage was just under 3.5 to 1 as of September 30. Accordingly, we are pushing back our timetable to achieve a leverage ratio of 3 to 1 or lower from our previous December 31, 2023 target to an expectation of that being achieved in early fiscal 2024. As I referenced earlier, we incurred a non-cash impairment charge of $13.8 million in the quarter due to decreased gross margin in the current period as a result of inflationary pressures and rising energy costs impacting our international reporting units operations. As a result, we performed an interim quantitative goodwill impairment test during the third quarter of 2023. This decreased gross margin, in addition to higher interest rates in the current period, contributed to an unfavorable decrease in this reporting unit value, which caused this impairment charge of $13.8 million, which was recorded within the International segment of our business. Excluding this non-cash impairment charge, the International segment achieved positive non-GAAP operating income as well as positive EBITDA for both the three months and nine months ended September 30, 2023 and they’ve also experienced strong growth over the prior year comparable period. We are optimistic for continued growth in this business in 2024, and beyond despite this economic headwind caused by this non-cash impairment, we will also benefit from pricing and cost improvements as part of Project Phoenix initiatives, which will be implemented during Q4 for International. The reorganizational cost of $2.7 million recorded during the quarter relate to professional fees and certain restructuring charges associated with the changes made to our organizational structure. In the third quarter of 2023, these charges included severance costs associated with the transformation of our Products and Systems segment as announced back on October 2nd. Before providing additional data and details on Project Phoenix, I would like to highlight that our Data Analytical Solutions revenue, which has experienced growth of nearly 16% for the year, is experiencing strong growth throughout all of 2023, and we believe this provides customers with a significant benefit being achieved through data analytical procedures, which in turn turns the data into actionable information, which our facility operators and our customer can use to maximize safety, enhance their productivity and optimize their budgets. But now let me provide a little more detail on Project Phoenix. A brief overview of actions taken thus far are as follows. First is strategic pricing, wherein we have developed and will further enhance a proactive structural price strategy to address inflationary costs being experienced within our business. This is the commercial function of Project Phoenix, which we mentioned earlier. Secondly, this reduction to overhead, our goal is to reduce overhead, as Manny said, to approximately 21% of total revenue by the end of 2024, primarily through a rationalization of the overhead workforce, including a targeted 15% reduction in administrative headcount without impacting the company’s technician workforce base or our ability to support operations and service our customers. And finally, the new leadership as a part of our transformation plan to improve shareholder value by lowering SG&A overheads, improving free cash flow, and accelerated growth, the board made recent changes to senior leadership within the company to further strengthen the organization and enhance the execution of the various initiatives comprising Project Phoenix. We anticipate the new commercial focus, which emerged from Project Phoenix, will help drive organic revenue growth in 2024, leading to a record adjusted EBITDA of greater than $88 million, primarily attributable to a significant increase in operating leverage arising from a meaningful reduction in overhead combined with profitable growth. More immediately, however, we are lowering our guidance ranges for fiscal 2023 with full-year revenue now expected to be between $695 million to $705 million from a previous $710 million to $720 million range, and adjusted EBITDA is now expected to be between $65 million and $68 million from a previous $68 million to $71 million range. The reduction in revenue and EBITDA are due to lower than previously forecasted fourth quarter results. Free cash flow guidance is also being lowered to between $7 million to $10 million from previously $23 million to $25 million range, which had excluded certain cash expenses being incurred to achieve the cost savings of Project Phoenix. This reduction in free cash flow guidance was due to an adverse day sales outstanding and buildup of AR and the incurrence of these cash expenses to achieve the Project Phoenix cost savings, and to a lesser extent, the increased capital expenditures to foster revenue growth. We anticipate a modest single-digit revenue growth in 2024, yet a significant expansion in adjusted EBITDA attributable to operating leverage and the ongoing benefits of Project Phoenix. Accordingly, we expect to generate an all-time adjusted EBITDA in fiscal 2024. This outlook includes approximately $20 million of incremental benefit from Project Phoenix in 2024, and this detail was delineated in a separate press release issued yesterday, which accompanied the earnings release, as Manny alluded to. Project Phoenix provides a roadmap for sustained cost savings and increased profitable growth with the ultimate goal of driving bottom-line improvement and increasing shareholder value. After thorough planning, we are now implementing or have implemented many of its initiatives, which are yielding immediate benefits. We appreciate your continued support and expect to reward your patients with significantly improved results in 2024. At this time, I would like to turn the call back over to Manny for his closing remarks before we move on to take your questions.